Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity
Tóm tắt
Từ khóa
Tài liệu tham khảo
Merrill, 1989, Modeling the interaction of HIV with the cells of the immune system, vol. 83
Tan, 1998, Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies, Math. Biosci., 147, 173, 10.1016/S0025-5564(97)00094-1
Ribeiro, 1999, A stochastic model for primary HIV infection: optimal timing of the therapy, AIDS, 13, 351, 10.1097/00002030-199902250-00007
Ribeiro, 2000, Production of resistant HIV mutants during antiretroviral therapy, Proc. Natl. Acad. Sci. USA, 97, 7681, 10.1073/pnas.97.14.7681
Ding, 1999, Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics, Math. Biosci., 160, 63, 10.1016/S0025-5564(99)00021-8
Essunger, 1994, Modeling HIV infection of CD4+ T-cells subpopulations, J. Theoret. Biol., 170, 367, 10.1006/jtbi.1994.1199
Kepler, 1998, Drug concentration heterogeneity facilitates the evolution of drug resistance, Proc. Natl. Acad. Sci. USA, 95, 11514, 10.1073/pnas.95.20.11514
Nowak, 1997, Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations, J. Theoret. Biol., 184, 203, 10.1006/jtbi.1996.0307
Perelson, 1993, Dynamics of HIV infection of CD4+ T cells, Math. Biosci., 114, 81, 10.1016/0025-5564(93)90043-A
Perelson, 1996, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 1582, 10.1126/science.271.5255.1582
Perelson, 1997, Decay characteristics of HIV-1-infected compartments during combination therapy, Nature, 387, 188, 10.1038/387188a0
Perelson, 1999, Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev., 41, 3, 10.1137/S0036144598335107
Wahl, 2000, Adherence and resistance: predictions for therapy outcome, Proc. Roy. Soc., Bio., 267, 835, 10.1098/rspb.2000.1079
H. Wu, D.R. Kuritzkes, M.S. Clair, H. Kessler, E. Connick, A. Landay, M. Heath-Chiozzi, F. Rousseau, L. Fox, J. Spritzler, J.M. Leonard, D.R. McClernon, M.M. Lederman, Interpatient variation of viral dynamics in HIV-1 infection: modeling results of AIDS clinical trials group protocol 315, in: The International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, Abstract 99 (1997)
Wu, 1999, Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials, Biometrics, 55, 410, 10.1111/j.0006-341X.1999.00410.x
Wu, 1999, Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints, J. Infect. Dis., 179, 799, 10.1086/314670
Ding, 2001, Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models, Biostatistics, 2, 13, 10.1093/biostatistics/2.1.13
Bonhoeffer, 1997, Pre-existence and emergence of drug resistance in HIV-1 infection, Proc. Roy. Soc., Bio., 264, 631, 10.1098/rspb.1997.0089
Frost, 1994, Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection, AIDS, 8, 323, 10.1097/00002030-199403000-00005
Mclean, 1991, Population dynamics of HIV within an individual after treatment with zidovudine, AIDS, 5, 485, 10.1097/00002030-199105000-00002
Mclean, 1992, Competition between zidovudine sensative and resistant strains of HIV, AIDS, 6, 71, 10.1097/00002030-199201000-00009
Nowak, 1991, Antigenic diversity thresholds and the development of AIDS, Science, 254, 963, 10.1126/science.1683006
Wei, 1995, Viral dynamics in human immunodeficiency virus type 1 infection, Nature, 373, 117, 10.1038/373117a0
Verme, 1992, Pharmacokinetics of quinidine in male patients: a population analysis, Clin. Pharmacokinet., 22, 468, 10.2165/00003088-199222060-00005
Davidian, 1995
Abbott Laboratories, Product Information. Website: http://www.norvir.com/hiv/hiv0044.htm
GlaxoSmithKline, Product Information. Website: http://www.gsk.com/products/prescriptionmedicines.shtml
Molla, 1996, Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nature Med., 2, 760, 10.1038/nm0796-760
Wainberg, 1996, Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase, AIDS, 10, S3, 10.1097/00002030-199612005-00002
Bonhoeffer, 1997, Evaluating treatment protocols to prevent antibiotic resistance, Proc. Natl. Acad. Sci. USA, 94, 12106, 10.1073/pnas.94.22.12106
Rowland, 1995
Sheiner, 1985, Modeling pharmacodynamics: parametric and nonparametric approaches, 139
Ho, 1995, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, 373, 123, 10.1038/373123a0
Nowak, 2000
Callaway, 2002, HIV-1 infection and low steady state viral loads, Bull. Math. Biol., 64, 29, 10.1006/bulm.2001.0266
R.E. Chaisson, When to start antiretroviral therapy? in: 9th Conference on Retroviruses and Opportunistic Infections, Abstract S17 (Session 21), Seattle, WA, February 24–28, 2002
Perelson, 1989, Modeling the interaction of the immune system with HIV, vol. 83
Ickovics, 1997, Adherence in AIDS clinical trial: a framework for clinical research and clinical care, J. Clin. Epidemiol., 50, 385, 10.1016/S0895-4356(97)00041-3
Holford, 2000, Simulation of clinical trials, Ann. Rev. Pharmacol. Toxicol., 40, 209, 10.1146/annurev.pharmtox.40.1.209
M. Pfister, L. Labbé, S.M. Hammer, J. Mellors, K.K. Bennett, S.L. Rosenkranz, L.B. Sheiner and the AIDS Clinical Trial Group Protocol 398 Investigators, Population Pharmacokinetics/Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir in AACTG Study 398. Under review at Antimicrobial Agents and Chemotherapy